CLDX

Business Context and Reporting Period

This Form 10-K covers the fiscal year ended December 31, 2007, for AVANT Immunotherapeutics, Inc. (Note: The request metadata lists "Celldex Therapeutics, Inc.", but the filing text identifies the registrant as AVANT, which merged with Celldex on March 7, 2008). AVANT is a biopharmaceutical company developing vaccines and immunotherapeutics. The company operates with a history of losses and relies on collaborations, government grants, and royalty income. A defining event for the period was the announcement and subsequent closing of a merger with Celldex Therapeutics, Inc., creating a combined entity with a diversified pipeline in oncology, infectious, and inflammatory diseases.

Key Financial Metrics

Note: Per share data and share counts have been adjusted to reflect a 1-for-12 reverse stock split effective March 7, 2008.

Material Changes vs. Prior Period

• Revenue Composition: Total revenue increased slightly by 3.5%. However, the mix shifted significantly. Product development and licensing revenue plummeted from $2.86 million in 2006 to $0.13 million in 2007, primarily due to the absence of the one-time $4 million milestone payment from GlaxoSmithKline (Glaxo) received in 2006 for European approval of Rotarix. Conversely, product royalty revenue surged to $4.49 million in 2007 from $0.67 million in 2006, driven by sales of Rotarix and Megan poultry vaccines.
• Government Contracts: Revenue from government contracts and grants decreased to $0.49 million in 2007 from $1.41 million in 2006. This decline reflects the termination of biodefense research contracts with DynPort Vaccine Company (DVC) in the third quarter of 2007 as part of a strategic restructuring.
• Operating Expenses: Total operating expenses increased by 2.4% to $27.96 million. R&D expenses rose due to increased royalty payments to Cincinnati Children's Hospital Medical Center (CCH) related to Rotarix royalties and higher clinical trial costs for the Ty800 vaccine. G&A expenses increased due to legal and professional fees associated with the Celldex merger.
• Liquidity: Cash and cash equivalents decreased significantly by approximately $25.25 million, from $40.91 million to $15.66 million. Net cash used in operating activities was $19.30 million in 2007, compared to net cash provided by operating activities of $27.00 million in 2006 (which included a large upfront payment from Paul Royalty Fund).

Guidance, Outlook, and Risks

Merger with Celldex: The most significant development is the completed merger with Celldex Therapeutics, Inc. (closed March 7, 2008). The transaction valued Celldex at approximately $75 million. Post-merger, former Celldex shareholders own 58% of the combined company, while former AVANT shareholders retain 42%. The combined entity aims to leverage AVANT's manufacturing capabilities and Celldex's oncology pipeline.

Product Outlook:

• Rotarix: Glaxo filed a Biologics License Application (BLA) with the FDA in 2007. A favorable recommendation from the FDA advisory committee was received in February 2008. AVANT expects a $1.5 million milestone payment upon U.S. approval and a potential $10 million milestone from Paul Royalty Fund upon U.S. launch (expected in 2008).
• Bacterial Vaccines: AVANT is focusing on CholeraGarde (Phase 2b) and Ty800 (Phase 2) for global health and travelers' markets. The company has exited the biodefense sector and is no longer investing in cardiovascular programs (TP10, CETi) independently, seeking partners for these assets.

Risks and Contingencies:

• Capital Requirements: The company has an accumulated deficit of $277.9 million. While management believes current cash ($15.66 million) is sufficient to fund operations beyond December 31, 2008, future profitability is uncertain. Additional capital may be required, potentially through equity dilution or debt.
• Regulatory Approval: Success depends heavily on FDA approval of Rotarix in the U.S. and other candidates. Delays or rejections would materially harm the business.
• Collaborator Dependence: AVANT relies on Glaxo for Rotarix commercialization and manufacturing. Disputes regarding royalty rates (Glaxo is paying at a lower rate due to patent assertions) and the timing of partner activities pose risks.
• Merger Integration: Risks include the inability to integrate operations successfully, retention of key personnel, and the failure of the combined pipeline to achieve commercial success.

Investor Verification Checklist

• Merger Status: Confirm the final terms and post-merger capitalization of the combined AVANT/Celldex entity, noting the 1-for-12 reverse stock split.
• Rotarix U.S. Approval: Monitor the FDA's final decision on the Rotarix BLA, as this triggers significant milestone payments ($1.5M from Glaxo, $10M from Paul Royalty Fund).
• Cash Runway: Verify the combined company's cash position and burn rate post-merger to assess the need for immediate capital raises.
• Royalty Dispute: Review the status of the royalty rate dispute with Glaxo regarding Rotarix sales in Australia and Europe, which impacts revenue recognition.
• Partnership Strategy: Assess progress in securing corporate partners for the TP10 (complement inhibitor) and CETi (cholesterol) programs, as AVANT has ceased independent investment in these areas.